Toward prostate cancer early detection in Iran

Asian Pacific Journal of Cancer Prevention

Volumn 10, Issue 3, 2009, Pages 413-418

  Mousavi, Seyed Mohsen ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Early detection; Iran; Prostate cancer

Indexed keywords

EID: 75149189717     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Abolhasani M, Chiaeo J V. (2004). Immunosuppressation by cell antigrowth factor of human carcinoma of prostate (JCA-1). Kerman University of Medical Sciences J, 11, 206-211 (in Persian).
2. Afshar Moghaddam N, Nasr M. (2006). Evaluation of neuroendocrine and proliferative markers in prostatic adenocarcinomas. IJMS??, 31, 18-21.
3. Amirmoghofran Z, Monabati A, Gholijani N. (2004). Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer. Path Oncol Res, 10, 37-41.
4. Amirmoghofran Z, Monabati A, Gholijani N. (2005). Apoptosis in prostate cancer: Bax correlation with stage. Int J Urol, 12, 340-5.
5. Assareh A, Moradi MH, Esmaeili V. (2007). A novel ensemble strategy for classification of prostate cancer protein mass spectra. Engineering in Medicine and Biology Society, 2007. 29th Annual International Conference of the IEEE, 22-6: 5987-90.
6. Babaei M, Mousavi S, Malek M, et al (2005). Cancer occurrence in Semnan Province, Iran: results of a population-based cancer registry. Asian Pac J Cancer Prev, 6, 159-64.
7. Babaian. RJ Mettlin C, Kane R, et al (1992). The relationship of prostate specific antigen to digital rectal examination and transrectal ultrasonography. Cancer, 69, 1195-200.
8. Babolhavaeji H. (2003). A report on prostate cancer among BPH patients which were operated in the Imam and Ekbatn Hospitals in Hamadan from 1986 to 1996. Scientific Journal of Hamadan University of Medical Sciences, 10, 69-70 (in Persian).
9. Bartsch G, Horninger W, Klocker H, et al (2001). Prostate cancer mortality after introduction of prostate specific antigen mass screening in the Federal State of Tyrol, Austria. Urology, 58, 417-24.
10. Basiri A, Mousavi SM, Naghavi M, Ahmadi Araghi I, Asbaghi Namini S (2008). Urologic diseases in Iran: Which are Public Health Priorities? East Med Hlth J, 14, 1338-48.
11. Bretton PR (1994). Prostate specific antigen and digital rectal examination in screening for prostate cancer. Southern Med J, 87, 720-3.
12. Falahatkar S, Atrkare Roshan Z, Askari SA, et al (2005). Prevalence of hidden prostatic carcinoma. J Guilan University of Medical Sciences, 14, 53-8.
13. Fallah M (2007). Cancer incidence in 5 provinces of Iran. Ardebil, Gilan, Mazandaran, Golestan and Kerman, 1996-2000. Academic dissertation, Faculty of Medicine of the University of Tampere.
14. Gao HW, Li YL, Wu S, et al (2005). Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen. Asian J Androl, 7, 159-63.
15. Ghabili K, Shoja MM, Agutter PS (2008). Piezoelectricity and prostate cancer: proposed interaction between electromagnetic field and prostatic crystalloids. Cell Biol Int, 32, 688-91.
16. Gholijani N, Monabati A, Amirghofran Z (2004). P53 protein expression and its relation to the apoptotic index in prostate cancer. Int J L??, 1, 34-40.
17. Habibi A, Manouchehri A, Diba MH, Sajadi M, Ghavam M (1975). Prostatic tumors in Iran. Int Surg, 60, 405-7.
18. Horninger W, Berger A, Pelzer A, et al (2005). Screening for prostate cancer: updated experience from the Tyrol study. Can J Urol, 12 (Suppl 1), 7-13.
19. Hosseini SY, Moharramzadeh M, Ghadian AR, et al (2007). Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran. Int J Urol, 14, 406-11.
20. IARC. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide (2002 estimates). http://www-dep.iarc.fr/(last accessed : Oct. 2008)
21. Jalal R, Ansari Majd S, Darvishalipour S, Roknizasdeh R (2007). Declining insulin growth factor receptor expression in human prostatic carcinoma cell line DU-145. Novin Bahar Genetic J, 2, 55-63 (in Persian).
22. Jamali Zavarehi M (1996). Statistical study and review of prostatatic latent carcinoma. Journal of Medical Faculty, Tehran University of Medical Sciences, 1, 37-41 (in Persian)
23. Jebelameli P. (1992). The role of PSA on early diagnosis of prostate cancer. Journal of Medical Faculty, Tehran University of Medical Sciences, 2, 19-21 (in Persian).
24. Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96.
25. Kermani T, Zardast M, Sabzevari AR, Varasteh AR (2004). Basal membrane changes and reticular fiber distribution in BPH and prostate carcinoma. Birjan University of Medical Sciences Journal, 11, 56-61 (in Persian)
26. Khoeia S, Goliaeia B, Neshasteh-Rizb A, Deizadjic A (2004).The role of heat shock protein 70 in the thermoresistance of prostate cancer cell line spheroids. FEBS Letters, 561, 144-8.
27. Khorramizadeh M R. , Aalizadeh N, Pezeshki M, et al (2005). Determination of gelatinase A using a modified indirect hemagglutination assay in human prostate cancer screening and assessment of its correlation with prostate-specific antigen parameters. Int J Urol, 12, 637-643
28. Li X, Tsuji L, Kuwahara M, et al (2004). Mass screening of prostate cancer in Changchun City of China. Int Urol Nephrol, 36, 541-8.
29. Mehrabi S, Ghafarian Shirazi H, Rasti M, Bayat B (2005). Analysis of serum prostate-specific antigen levels in men aged 40 years and older in Yasuj, Iran. Urol J, 2, 189-92.
30. Middle East Cancer Consortium (MECC) monograph, Executive summary , 2005; 15: Xiii
31. Mofid B, Jalali Nodushan M, Rakhsha A, Zeinali L, Mirzaei H (2007). Relation between HER-2 gene expression and Gleason score in patients with prostate cancer. Urol J, 4, 101-4.
32. Mohagheghi M, Mosavi-Jarrahi A (2006). Cancer Incidence in the Population of Tehran Metropolis, 1998-2001. The Cancer Institute Cancer Research Center, Tehran, Iran (in Persian)
33. Mokhtari MJ, Motamed N, Shokrgozar MA. (2008). Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line. Cell Biol Int, 32, 888-92.
34. Mousavi SM, Alamolhoda AA, Gouya MM, Lickiss NJ (2008). Implementation of comprehensive national cancer control program in Iran: an experience in a developing country. Ann Oncol, 19, 398-400.
35. Mousavi SM, Gouya MM, Ramazani R, et al (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63.
36. Mousavi SM, Harirchi I, Ebrahimi M, et al (2009). Screening of breast cancer in Iran: A challenge for health policy makers. The Breast Journal, 14, 605-6.
37. Mousavi SM, Ramazani R, Davanloo M, Hajsadeghi N, Jalal R, Ramezan Shirazi M. National Cancer Registry Report 2005-2006. Ministry of Health, Deputy to Health Directory, Tehran, Iran; CDC_ Cancer Office: Feb.2008
38. Mousavi SM, Zheng T, Dastgiri S, Miller AB (2009). Age distribution of breast cancer in the Middle East, implications for screening. The Breast Journal, 14, (in press)
39. Naghavi M, Jafari N (2007). Mortality views in 29 Provinces of Iran in 2004- Ministry of Health, Deputy for Health Directory, Research and Development Office, Tehran, Iran, (in Persian).
40. Naghavi M ( 2006). Mortality views in 29 Provinces of Iran in 2004- Ministry of Health, Deputy for Health Directory, Research and Development Office, 111-191 (in Persian).
41. Omidi AA, Kalantari MR (2001). Differentiation between carcinoma and nodular hyperplasia of prostate with AgNOR staining. Iran J Med Sci, 4, 62-70 (in Persian).
42. Ousati Ashtiani Z, Ayati M, Modarresi MH, et al (2009). Association of TGIFLX/Y mRNA expression with prostate cancer. Med Oncol, 26, 73-7.
43. Parvin M, Bidari Zerehpoush F (2001). A survey on the efficacy of AgNOR staining for differentiation between carcinoma and BPH. Iranian Urol J, 29, 49-54 (in Persian).
44. Pourmand G, Salem S, Mehrsai A, et al (2007). The risk factors of prostate cancer: a multicentric case-control study in Iran. Asian Pac J Cancer Prev, 8, 422-8.
45. Pourmand G, Ziaee AA, Abedi AR, et al (2007). Role of PTEN gene in progression of prostate cancer. Urol J, 4, 95-100
46. Rajabi P, Noori M, Kalantarain M (2001). The role of AgNOR staining on differentiating between benign hyperplasia, atypical adenomatosis hyperplasia, and adenocarcinoma of prostatae. J Isfahan Faculty of Medicine, 19, 38-41 (in Persian).
47. Rezaeian M, Tabatabaei Z, Naeimi R, et al (2006). Knowledge, attitude and practice of Rafsanjan males pensioners toward prostate cancer prevention in 2006. Ofoghe Danesh Journal of Gonabad University of Medical Sciences, 12, 19-26 (in Persian).
48. Sadjadi A, Malekzadeh R, Derakhshan M H, et al (2003). Cancer occurrence in Ardabil: Results of a population-based cancer registry from Iran. Int J Cancer, 107, 113-8.
49. Sadjadi A, Zahedi MJ, Darvish Moghadam S, et al (2007). The First population-based cancer survey in Kerman Province of Iran. Iranian J Publ Health, 36, 26-34.
50. Sadjadi AR, Nooraie M, Ghorbani A, Alimohammadian M, et al (2007). The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iranian Med, 10, 481-5.
51. Safarinejad MR (2005). Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer. Urol Oncol, 23, 93-101.
52. Safarinejad MR (2006). Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran. Ann Oncol, 17, 1166-71.
53. Safarinejad MR (2009). Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: A Phase II study. Urol Oncol, (in press).
54. Salehi M, Falahat Kar S, Latifi L (2002). Patients with BPH operated in Urology ward. J Faculty of Medicine of Guilan University of Medical Sciences, 11, 66-70 (in Persian).
55. Semnani S, Roshandel G, Keshtkar A, et al (2008). Golestan population-based cancer registry. Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences. 84-95 (in Persian).
56. Shariftabrizi A, Khorramizadeh MR, Saadat F, et al (2005). Concomitant reduction of matrix metalloproteinase-2 secretion and intracellular reactive oxygen species following anti-sense inhibition of telomerase activity in PC-3 prostate carcinoma cells. Mol Cell Biochem, 273, 109-16.
57. Soheili Z, Manoshehr Z, Samiee S, et al (2006). PI3K gene expression of P3 and DU145 prostate cancer stem cell. Feiz Scientific Research J, 10, 1-8 (in Persian)
58. Song C, Ahn H, Lee MS, Park J, et al (2008). Korean Urological Oncology Society. Mass screening for prostate cancer in Korea: a population based study. J Urol, 180, 1949-52.
59. Teimourian S, Jalal R, Sohrabpour M, Goliaei B (2006). Down-regulation of Hsp27 radiosensitizes human prostate cancer cells. Int J Urol, 13, 1221-5.
60. Tracey E, Baker D, Chen W, Stavrou E, Bishop J (2007). Cancer in New South Wales: Incidence, Mortality and Prevalence, 2005. Sydney: Cancer Institute NSW.
61. Watanabe H (2001). Mass screening program for prostatic cancer in Japan. Int J Clin Oncol, 6, 66.
62. Zhao XJ, Kong XB, Wang WH (2003). Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer. Zhonghua Nan Ke Xue, 9, 563-5,568.
63. Zolfaghari A, Djakiew D (1996). Inhibition of chemomigration of human prostatic carcinoma cell line (TSU-pr1) by inhibition of epidermal growth factor receptor function. Prostate, 28, 232-8.